PERSEUS PROTEOMICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 327 JPY | +2.19% |
|
+6.17% | -47.09% |
| Sales 2022 | 71M 452K | Sales 2023 | 94M 598K | Capitalization | 3.5B 22.31M |
|---|---|---|---|---|---|
| Net income 2022 | -599M -3.81M | Net income 2023 | -786M -5M | EV / Sales 2022 | 23.6 x |
| Net cash position 2022 | 3.21B 20.46M | Net cash position 2023 | 2.44B 15.56M | EV / Sales 2023 | 11.3 x |
| P/E ratio 2022 |
-7.64
x | P/E ratio 2023 |
-4.46
x | Employees | 24 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.87% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.19% | ||
| 1 week | +6.17% | ||
| Current month | -4.66% | ||
| 1 month | -1.21% | ||
| 3 months | -11.86% | ||
| 6 months | -55.75% | ||
| Current year | -47.09% |
1 week
309.00
383.00
1 month
298.00383.00
Current year
291.00765.00
1 year
255.00879.00
3 years
255.001 022.00
5 years
255.001 022.00
10 years
255.001 022.00
| Managers | Title | Age | Since |
|---|---|---|---|
Takuya Yokogawa
PSD | President | 63 | 18-02-28 |
Tadashi Matsuura
CTO | Chief Tech/Sci/R&D Officer | 65 | 05-04-30 |
Yasuo Ichinose
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takao Hamakubo
BRD | Director/Board Member | - | - |
Nobuo Hanai
BRD | Director/Board Member | 71 | 21-02-28 |
| Chief Administrative Officer | 68 | 19-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 327 | +2.19% | 344,600 |
| 24-05-23 | 320 | -3.90% | 489,400 |
| 24-05-22 | 333 | -5.40% | 738,000 |
| 24-05-21 | 352 | -1.12% | 1,751,500 |
| 24-05-20 | 356 | +15.58% | 2,461,300 |
Delayed Quote Japan Exchange, May 24, 2024 at 02:00 am EDT
More quotes
Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
Sector
Pharmaceuticals
Calendar
2024-11-07
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -47.09% | 25.68M | |
| -2.00% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.86% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +4.94% | 8.94B |
- Stock Market
- Equities
- 4882 Stock
